SAGA Diagnostics
Liquid biopsy testing specialists. Ultrasensitive cancer diagnosis and monitoring to 0.001% variant frequency.
Based based in European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA), SAGA Diagnostics works in biotechnology, genetics, medical, oncology, founded in 2016.
Within the biotechnology, genetics, medical, oncology space, the company focuses on its core offering rather than a broad product line.
Its base of operations is European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA).
It is recorded at the Series_A stage.
Its team size is recorded as c_00011_00050 employees.
Public records show total funding of about $18M.
| Sector | Biotechnology, Genetics, Medical, Oncology |
|---|---|
| Headquarters | European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA) |
| Country | SE |
| Founded | 2016 |
| Employees | c_00011_00050 |
| Stage | series_a |
| Total funding | $17,960,870 |
Website: sagadiagnostics.com
Browse related
Emails and contact routes are reserved for registered members.
Create a free account
Create a free account